Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19

Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19

We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wang-Da Liu, Chien-Ching Hung, Jann-Tay Wang, Ming-Jui Tsai, Po-Hsien Kuo, Tai-Ling Chao, Szu-Min Hsieh, Wang-Huei Sheng, Yee-Chun Chen, Sui-Yuan Chang, Shan-Chwen Chang
Format: article
Langue:EN
Publié: Elsevier 2021
Sujets:
Antiretroviral therapy
Coronavirus
Enzyme-linked immunosorbent assay (ELISA)
Plaque reduction assay
Severe acute respiratory syndrome
Medicine (General)
R5-920
Accès en ligne:https://doaj.org/article/6c68ae0190b84843af686b82c3f5a65f
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms.

Documents similaires